Upon Further Review

Stanford researcher writes that readers should check the effect size of results instead of looking at the p-value.

Researcher criticizes the many ways opposing viewpoints and dissenting voices are squashed in the field of medicine.

A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.

An issue of Lancet Psychiatry is devoted to clarifying the lack of efficacy for Zoloft (sertraline).

New meta-scientific review questions the evidence for the gold standard psychotherapies and empirically supported treatments.

Current standards for clinical trials rely on statistical methods that allow for ineffective treatments to gain approval.

A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.

A new review, published in BMJ Evidence-Based Medicine, concludes that antidepressants should not be used as the risks outweigh evidence for benefits.

Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.

Researchers critique the German S3 guidelines for depression promoting antidepressants.

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.

An analysis of last year’s positive finding in The Lancet about antidepressant efficacy shows errors, obfuscations, and misrepresentations.

Researchers question biases of preliminary trials that found that sodium nitroprusside, an antihypertensive drug, has positive effects on schizophrenia symptoms.

A new study casts doubt on whether such biotypes for depression exist.

Could the statistical phenomenon of regression to the mean be responsible for the dramatic effects of placebo—as well as the supposed effectiveness of some psychiatric drugs?

Researchers examine how rapid discontinuation can mimic the relapse of mental health symptoms and confound psychiatric drug studies.

Neuroscience researchers find no differences in brain connectivity between children with diagnoses of autism, ADHD, and those with no diagnoses.

The candidate-gene approach to depression goes unsupported and is likely based on bad science, new research finds.

The latest issue of the journal Behavioral and Brain Sciences features several prominent researchers arguing that mental health concerns are not “brain disorders.”

An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.

A new study demonstrates how the choice of statistical techniques when examining data plays a large role in scientific outcomes.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.

Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.

A new study finds that sponsors of clinical trials in the EU continue to fail at reporting their results as required by recent legislation.

Reanalysis of the original primary outcome measure in the STAR*D study suggests STAR*D findings inflate improvement on antidepressant medication and exclusion criteria in conventional clinical trials results in overestimation of antidepressant efficacy.